Health Testing and Trials - Publications - Faculty & Research - Harvard Business School

Filter Results: (629)

Filter Results: (629)

Show Results For

← Page 6 of 629 Results →

Sort by

Are you looking for?

→Search All HBS Web

June 2021
Case

HelloSelf: Launch

By: John R. Wells and Benjamin Weinstock

In April 2021, Charles Wells, founder and CEO of HelloSelf was reflecting on the company’s progress since it launched two years earlier. HelloSelf’s goal was to help the mentally ill recover and those who were mentally fit to stay well and feel even better. To do this,... View Details

Keywords: Mental Health; Health Care and Treatment; Internet and the Web; Growth and Development Strategy; Great Britain

February 2019
Article

Who Benefits Most in Disease Management Programs: Improving Target Efficiency

By: Timothy Simcoe, Maryaline Catillon and Paul Gertler

Disease management programs aim to reduce cost by improving the quality of care for chronic diseases. Evidence of their effectiveness is mixed. Reducing health care spending sufficiently to cover program costs has proved particularly challenging. This study uses a... View Details

Keywords: Health Economics; Target Efficiency; Diabetes; Disease Management; Program Evaluation; Heterogeneity; Economics; Health; Quality; Health Care and Treatment; Cost Management; Health Industry

Find at Harvard

15 Jun 2020
Research & Ideas

A Mass Crisis Can Overwhelm Health Care. Liberia Found a Solution.

test people, then process the tests and take them to a waiting area.” When Ebola began ravaging the country in 2014, Liberia’s government came knocking on Last Mile Health’s... View Details

Keywords: by Rachel Layne; Health

September 2013 (Revised August 2014)
Case

Claritas Genomics

By: Robert F. Higgins and Matthew Preble

Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details

October 2013
Case

FasterCures: Removing Barriers to Treatments

By: Richard G. Hamermesh and James Weber

In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details

Article

Measuring the Scientific Effectiveness of Contact Tracing: Evidence from a Natural Experiment

By: Thiemo Fetzer and Thomas Graeber

Contact tracing has for decades been a cornerstone of the public health approach to epidemics, including Ebola, severe acute respiratory syndrome, and now COVID-19. It has not yet been possible, however, to causally assess the method’s effectiveness using a randomized... View Details

Keywords: COVID-19; Contact Tracing; Public Health; Infectious Diseases; Health Pandemics

November 2018
Case

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details

Keywords: Cancer; Therapeutics; Drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges

July 2021
Article

Creating Exercise Habits Using Incentives: The Trade-off Between Flexibility and Routinization

By: John Beshears, Hae Nim Lee, Katherine L. Milkman, Robert Mislavsky and Jessica Wisdom

Habits involve regular, cue-triggered routines. In a field experiment, we tested whether incentivizing exercise routines—paying participants each time they visit the gym within a planned, daily two-hour window—leads to more persistent exercise than offering flexible... View Details

Keywords: Behavior And Behavioral Decision Making; Healthcare; Exercise; Habit; Routine; Health; Behavior; Decision Making

Find at Harvard

June 2014 (Revised April 2015)
Case

OrthoChoice: Bundled Payments in the County of Stockholm (A)

By: Michael E. Porter, Clifford M. Marks and Zachary C. Landman

It was the waiting that drew the attention of the Stockholm County Council. In 2008, patients seeking a hip or knee replacement in Stockholm County faced wait times of up to two years of sometimes debilitating pain, intermittent missed work and income, and the trials... View Details

Keywords: Bundled Payment; Health Care Quality; Health Care; Sweden; Hip Replacement; Knee Replacement; Orthopedics; Health Care and Treatment; Health Disorders; Health; Health Industry; Sweden

November 2014
Teaching Note

Claritas Genomics

By: Robert F. Higgins and Matthew G. Preble

Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details

Keywords: Healthcare; Healthcare Startups; Genetic Testing; Genetics Diagnostics; Spinning Out Hospital Services; Spin-out; Health Care and Treatment; Genetics; Entrepreneurship; Health Industry; Health Industry; United States

March 2016
Article

Using Quality Improvement Methods and Time-Driven Activity-Based Costing to Improve Value-Based Cancer Care Delivery at a Cancer Genetics Clinic

By: R.Y. Tan, M. Met-Domestici, K. Zhou, A.B. Guzman, S.T. Lim, K.C. Soo, T.W. Feeley and J. Ngeow

Purpose:
To meet increasing demand for cancer genetic testing and improve value-based cancer care delivery, National Cancer Centre Singapore restructured the Cancer Genetics Service in 2014. Care delivery processes were redesigned. We sought to improve access by... View Details

Keywords: Cancer Treatment; Value Based Health Care; Time-Driven Activity-Based Costing; Health Care and Treatment; Quality; Performance Improvement; Activity Based Costing and Management

January 2001
Case

Abgenix and the XenoMouse

By: Robert J. Dolan

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details

Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry

12 Jul 2017
Working Paper Summaries

Task Selection and Workload: A Focus on Completing Easy Tasks Hurts Long-Term Performance

Keywords: by Diwas S. KC, Bradley R. Staats, Maryam Kouchaki, and Francesca Gino; Health

Article

Medical Group Structural Integration May Not Ensure That Care Is Integrated, From The Patient's Perspective

By: Michaela J. Kerrissey, Jonathan Clark, Mark Friedberg, Wei Jiang, Ashley Kay Fryer, Molly Frean, Stephen Shortell, Patricia Ramsay, Lawrence Casalino and Sara J. Singer

Structural integration is increasing among medical groups, but whether these changes yield care that is more integrated remains unclear. We explored the relationships between structural integration characteristics of 144 medical groups and perceptions of integrated... View Details

Keywords: Integration; Health Care Delivery; Organization Structure; Organizational Structure; Health Care and Treatment; Perception; Perspective; Health Industry; United States

Find at Harvard

August 2018 (Revised February 2023)
Case

Hubble Contact Lenses: Data Driven Direct-to-Consumer Marketing

By: Jill Avery and Ayelet Israeli

As its Series A extension round approaches, the founders of Hubble, a subscription-based, social-media fueled, direct-to-consumer (DTC) brand of contact lenses, are reflecting on the marketing strategies that have taken them to a valuation of $200 million and debating... View Details

March 2023
Case

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details

September 2020
Article

Regulatory Sandboxes: A Cure for mHealth Pilotitis?

By: Abhishek Bhatia, Rahul Matthan, Tarun Khanna and Satchit Balsari

Mobile health (mHealth) and related digital health interventions in the past decade have not always scaled globally as anticipated earlier despite large investments by governments and philanthropic foundations. The implementation of digital health tools has suffered... View Details

Keywords: COVID-19; mHealth; Digital Health; Design Thinking; Regulation; Intervention; Regulatory Sandbox; Health Care and Treatment; Technological Innovation; Design; Governing Rules, Regulations, and Reforms; India

December 2014 (Revised August 2015)
Case

Improving Melanoma Screening: MELA Sciences

By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols

MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details

Keywords: Healthcare Industry; Health Care; Health; Health Care and Treatment; Health Testing and Trials; Health Industry; United States

March 2019
Case

DayTwo: Going to Market with Gut Microbiome

By: Ayelet Israeli and David Lane

DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details

November 2009
Case

The Explosion of Genetic Testing: Opportunities and Challenges

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details

Keywords: Genetics; Health Care and Treatment; Health Testing and Trials; Disruptive Innovation; Business Model; Health Industry; Health Industry

←
6
7
…
31
32
→